271 related articles for article (PubMed ID: 20546455)
1. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
[TBL] [Abstract][Full Text] [Related]
2. A gene therapy renaissance?
Rasko JE
J Gastroenterol Hepatol; 2010 May; 25(5):848-50. PubMed ID: 20546435
[No Abstract] [Full Text] [Related]
3. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
4. In vivo selection of hepatocytes transduced with adeno-associated viral vectors.
Chen SJ; Tazelaar J; Moscioni AD; Wilson JM
Mol Ther; 2000 May; 1(5 Pt 1):414-22. PubMed ID: 10933962
[TBL] [Abstract][Full Text] [Related]
5. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
6. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation restores liver function in Fah-knockout mice.
Eggenhofer E; Popp FC; Renner P; Slowik P; Neuwinger A; Piso P; Geissler EK; Schlitt HJ; Dahlke MH
Exp Hematol; 2008 Nov; 36(11):1507-13. PubMed ID: 18715687
[TBL] [Abstract][Full Text] [Related]
8. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
9. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
10. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery.
Held PK; Olivares EC; Aguilar CP; Finegold M; Calos MP; Grompe M
Mol Ther; 2005 Mar; 11(3):399-408. PubMed ID: 15727936
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
12. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death.
Vogel A; van Den Berg IE; Al-Dhalimy M; Groopman J; Ou CN; Ryabinina O; Iordanov MS; Finegold M; Grompe M
Hepatology; 2004 Feb; 39(2):433-43. PubMed ID: 14767996
[TBL] [Abstract][Full Text] [Related]
13. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.
Overturf K; Al-Dhalimy M; Tanguay R; Brantly M; Ou CN; Finegold M; Grompe M
Nat Genet; 1996 Mar; 12(3):266-73. PubMed ID: 8589717
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
15. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
Wu G; Liu N; Rittelmeyer I; Sharma AD; Sgodda M; Zaehres H; Bleidissel M; Greber B; Gentile L; Han DW; Rudolph C; Steinemann D; Schambach A; Ott M; Schöler HR; Cantz T
PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
[TBL] [Abstract][Full Text] [Related]
16. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
[TBL] [Abstract][Full Text] [Related]
17. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development.
Marhenke S; Lamlé J; Buitrago-Molina LE; Cañón JM; Geffers R; Finegold M; Sporn M; Yamamoto M; Manns MP; Grompe M; Vogel A
Hepatology; 2008 Aug; 48(2):487-96. PubMed ID: 18666252
[TBL] [Abstract][Full Text] [Related]
18. The mechanism of naked DNA uptake and expression.
Wolff JA; Budker V
Adv Genet; 2005; 54():3-20. PubMed ID: 16096005
[TBL] [Abstract][Full Text] [Related]
19. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
20. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]